Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 12914
Sealed predictions
- AMOTL2 in dopamine neurons, braak-0.86 (p 0.003) → -0.38 (p 0.316)receipt 12922
Swarm cases
receipt 12922: AMOTL2 in dopamine neurons, braak
- power
- full sample -0.58 (p 0.013, n 18), 95% CI -0.82 to -0.15. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.69 (p 0.0014, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.71 (p 9.6e-4, n 18). not the mix.
- skeptic
- leave-one-out range -0.75 to -0.52, sign flips 0; without severely affected donors -0.58 (p 0.013, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for AMOTL2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts